FDA Approves KedRAB [rabies immune globulin (Human)] for Post-Exposure Prophylaxis of Rabies Infection
Fort Lee, NJ/Rehovot, Israel – August 25, 2017 - Kedrion Biopharma and Kamada Ltd. (NASDAQ and TASE: KMDA), two leading human-derived protein therapeutics companies, today announced that KedRAB™ [rabies immune globulin (Human)] has received U.S....
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Gammagard Liquid | Israel Health | Middle East Health | Privigen | Rabies